A detailed history of Livelsberger Financial Advisory transactions in Abb Vie Inc. stock. As of the latest transaction made, Livelsberger Financial Advisory holds 4,093 shares of ABBV stock, worth $718,648. This represents 16.94% of its overall portfolio holdings.

Number of Shares
4,093
Previous 4,076 0.42%
Holding current value
$718,648
Previous $699 Million 15.6%
% of portfolio
16.94%
Previous 10.43%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 21, 2024

BUY
$163.84 - $199.33 $2,785 - $3,388
17 Added 0.42%
4,093 $808 Million
Q2 2024

Aug 05, 2024

BUY
$154.79 - $180.76 $3,095 - $3,615
20 Added 0.49%
4,076 $699 Million
Q1 2024

May 21, 2024

BUY
$159.82 - $182.1 $2,716 - $3,095
17 Added 0.42%
4,056 $655 Million
Q4 2023

Mar 22, 2024

BUY
$137.6 - $154.97 $555,766 - $625,923
4,039 New
4,039 $626 Million

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $310B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Livelsberger Financial Advisory Portfolio

Follow Livelsberger Financial Advisory and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Livelsberger Financial Advisory, based on Form 13F filings with the SEC.

News

Stay updated on Livelsberger Financial Advisory with notifications on news.